Abstract 97P
Background
Patients with CRC are predisposed to CVD due to shared risk factors and sequalae of cancer treatments. We aimed to assess if rural residence and low SES modify the risk of developing new-onset CVD in patients with CRC.
Methods
Patients diagnosed with stage I-III CRC without any baseline CVD in a large Canadian province from 2004 to 2017 were identified using the population-based registry. Postal codes were linked with Census data to determine rural residence as well as SES. Low income and low education were defined as <46,000 CAD/annum and a neighborhood population in which <80% attended high school. The presence of myocardial infarction, heart failure, arrythmia or cerebrovascular accident constituted as CVD.
Results
We identified 12,170 eligible patients. The median age was 65 years and 43.7% were women. Stage I, II and III CRC were diagnosed in 30.2%, 31.4% and 38.5% patients. One-fourth of patients resided rurally, while 78.8% and 59.5% belonged to low income and low education neighborhoods. At a median follow-up of 62.2 months, 4,163 (34.2%) developed new-onset CVD, which was more common in patients from rural communities (36.8% vs 33.3%, P<.001), low income (35.7% vs 28.8%, P<.001) and low education (36.0% vs 31.6%, P<.001) neighborhoods. After adjusting for age, sex and treatment, low income (odds ratio [OR], 1.22; 95% confidence interval [CI], 1.10-1.37; P<.001) and low education (OR, 1.10; 95% CI, 1.01-1.20; P=.044) were associated with a higher likelihood of developing CVD, while rural residence was not. In a Cox regression model adjusting for measured confounders, low income (hazard ratio, 1.14; 95% CI, 1.03-1.25; P=.010) but not low education and rural residence predicted for worse overall.
Conclusions
In this large population-based study, patients from low SES neighborhoods were at an increased risk of developing new-onset CVD. However, the effect on survival was attenuated, likely reflecting access to universal healthcare in Canada. SES disparities in physical activity, diet, and other lifestyle modification strategies may explain the different risk profiles for CVD and should be the focus of public health efforts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
349P - Proteinuria in patients treated with ramcirumab increases the risk of renal dysfunction
Presenter: Kenta Hayashino
Session: e-Poster Display Session
350P - Rheumatologic immune related adverse events (irAEs) secondary to immune checkpoint inhibitor (ICI) therapy: A Western Australia experience
Presenter: Azim Khan
Session: e-Poster Display Session
351P - Valvular heart diseases in patients treated for breast cancer
Presenter: Ekaterina Kushnareva
Session: e-Poster Display Session
352P - Reproductive system disorders following chemotherapy in patients with breast cancer in Yogyakarta, Indonesia
Presenter: Irfan Haris
Session: e-Poster Display Session
353P - Survey for geriatric assessment in practising oncologists in India
Presenter: Vikas Talreja
Session: e-Poster Display Session
354P - Knowledge, perception, and attitude of oncology-related healthcare providers on complementary and alternative medicine (CAM)
Presenter: Chih Kiang Tan
Session: e-Poster Display Session
355P - Impact of comorbidities and rurality on treatment commencement, completion and outcomes, and health related quality of life, for geriatric oncology patients: Preliminary findings from a regional Australian study
Presenter: Mathew George
Session: e-Poster Display Session
357P - Comparison between immunotherapy and chemotherapy as neoadjuvant setting in resectable non-small cell lung cancer: A systematic review and meta-analysis of prospective trials
Presenter: Chao Zhang
Session: e-Poster Display Session
358P - Adjuvant tyrosine kinase inhibitors in non-squamous non-small cell lung cancer with EGFR driver mutations: An updated meta-analysis of randomized trials
Presenter: Joanmarie Balolong-Garcia
Session: e-Poster Display Session
359P - The role of adjuvant targeted therapy for postoperative EGFR mutant non-small cell lung cancer: A network meta-analysis
Presenter: Guang Ling Jie
Session: e-Poster Display Session